IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice-Reference-Cited by-同舟云学术

IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice

Published:2014-12 Issue:6 Volume:134 Page:1422-1432.e11
ISSN:0091-6749
Container-title:Journal of Allergy and Clinical Immunology
language:en
Short-container-title:Journal of Allergy and Clinical Immunology

Author:

Li Dong,Guabiraba Rodrigo,Besnard Anne-Gaëlle,Komai-Koma Mousa,Jabir Majid S.,Zhang Li,Graham Gerard J.,Kurowska-Stolarska Mariola,Liew Foo Y.,McSharry Charles,Xu Damo

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference46 articles.

1. Modeling pulmonary fibrosis with bleomycin;Mouratis;Curr Opin Pulm Med,2011

2. Studies on bleomycin;Umezawa;Cancer,1967

3. Bleomycin: revival of an old drug;Mir;Gen Pharmacol,1996

4. Mechanisms of fibrosis: therapeutic translation for fibrotic disease;Wynn;Nat Med,2012

5. Molecular targets in pulmonary fibrosis: the myofibroblast in focus;Scotton;Chest,2007

Cited by 332 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ablation of LRP6 in alpha-smooth muscle actin-expressing cells abrogates lung inflammation and fibrosis upon bleomycin-induced lung injury;2024-09-10

2. Tff1-expressing Tregs in lung prevent exacerbation of Bleomycin-induced pulmonary fibrosis;Frontiers in Immunology;2024-09-02

3. Trimetazidine Alleviates Bleomycin-Induced Pulmonary Fibrosis by Targeting the Long Noncoding RNA CBR3-AS1-Mediated miRNA-29 and Resistin-Like Molecule alpha 1: Deciphering a Novel Trifecta Role of LncRNA CBR3-AS1/miRNA-29/FIZZ1 Axis in Lung Fibrosis;Drug Design, Development and Therapy;2024-09

4. Interleukin-33 promotes intrauterine adhesion formation in mice through the mitogen-activated protein kinase signaling pathway;Communications Biology;2024-08-20

5. Selective production of IL-33-neutralizing autoantibody ameliorates asthma responses and severity;Clinical Immunology;2024-07